rss
Frontline Gastroenterol doi:10.1136/fg.2010.003558
  • New ways of working
  • Review

Establishing a biologics service for patients with inflammatory bowel disease

  1. S M Everett
  1. Department of Gastroenterology, Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
  1. Correspondence to Dr P J Hamlin, Department of Gastroenterology, Leeds Gastroenterology Institute, D Floor, Clarendon wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK; medjph{at}leeds.ac.uk
  • Accepted 28 January 2011
  • Published Online First 21 April 2011

Abstract

The use of anti-TNF therapy in the management of Crohn's disease and, to a lesser extent ulcerative colitis, is increasing. This article aims to discuss the practicalities of establishing a biologics service for patients with inflammatory bowel disease. Current guidelines on the use of these drugs are reviewed followed by a discussion on the choice of which anti-TNF agent to use based on costs and patient choice. A model for the initiation, administration, monitoring and assessment of patients receiving anti-TNF therapy is proposed. The need for a national biologics registry is highlighted in the summary.

Footnotes

  • Competing interests PJH and SME were both advisory board members for Schering Plough/MSD and Abbott pharmaceuticals. PJH advised on the draft NICE benchmarking guide for commissioning of anti-TNF therapies. Schering Plough/MSD provided the salary for an IBD clinical nurse specialist in Leeds.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of FG.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article